Stockpolly
Search
ATOS · NASDAQ · Biotechnology

Atossa Therapeutics (ATOS)

Develops oral (Z)-endoxifen for breast cancer and selected rare diseases.

$2.49
At close+0.07 (+2.89%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
79776779911109
Research & development464433465655
333434344554
Selling & marketing000000000000
General & administrative333434344554
Other expenses000000000000
Operating income−7−9−7−7−6−7−7−9−9−11−10−9
1111−11111000
Interest income111111111000
Interest expense010000000000
Other non-operating income0−1−1−11−1−1−1−1000
Income before tax−6−8−6−6−7−6−7−8−9−11−10−8
Net income from continuing operations−6−8−6−6−7−6−7−8−9−11−10−8
Net income−6−8−6−6−7−6−7−8−9−11−10−8
EPS, basic−$0.74−$0.93−$0.70−$0.72−$0.86−$0.75−$0.78−$0.98−$1.01−$1.27−$1.11−$0.95
EPS, diluted−$0.74−$0.93−$0.70−$0.72−$0.86−$0.75−$0.78−$0.98−$1.01−$1.27−$1.11−$0.95
Weighted average shares, basic888888999999
Weighted average shares, diluted888888999999
EBITDA−7−8−6−6−7−6−7−8−9−11−10−8
Depreciation & amortization000000000000
EBIT−7−8−6−6−7−6−7−8−9−11−10−8